Aerovate Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
July 02, 2021 16:01 ET
|
Aerovate Therapeutics, Inc.
BOSTON, July 02, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of...
Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering
June 29, 2021 22:59 ET
|
Aerovate Therapeutics, Inc.
BOSTON, June 29, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of...
Aerovate Therapeutics Appoints Timothy Noyes as Chief Executive Officer
May 18, 2021 07:00 ET
|
Aerovate Therapeutics, Inc.
BOSTON, May 18, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Aerovate), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of...